Gore PharmBio Introduces 116mL and 232mL Protein Capture Devices With Protein A to Increase Productivity and Throughput for Antibody Purification

×

Error message

  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

W. L. Gore & Associates, Inc. (Gore), a global materials science company, continues to build on its growing portfolio of protein capture devices with the introduction of its new 116mL and 232mL GORE Protein Capture Devices with Protein A.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, April 5, 2022
Information
Tags: 
Research, Medical Devices, Genetics, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, Science, Multimedia, LC, Solution, Associate, GMP, DBC, Polytetrafluoroethylene, Fine chemical
Geotags: 
UNITED STATES, NORTH AMERICA, DELAWARE
⚠ generated by AI ↴
Organisation: 
Gore
Summary
Key Points: 
  • W. L. Gore & Associates, Inc. (Gore), a global materials science company, continues to build on its growing portfolio of protein capture devices with the introduction of its new 116mL and 232mL GORE Protein Capture Devices with Protein A.
  • The offerings follow commercial availability of its 58mL Protein Capture Device in Q4 of 2021.
  • View the full release here: https://www.businesswire.com/news/home/20220405005200/en/
    GORE Protein Capture Devices with Protein A (Photo: Business Wire)
    With these new, larger capacity 116mL and 232mL sizes, Gore continues to expand its GMP solutions, joining its current 9mL and 58mL devices.
  • Key features of the 116mL and 232mL GORE Protein Capture Devices with Protein A include:
    W. L. Gore & Associates is a global materials science company dedicated to transforming industries and improving lives.


W. L. Gore & Associates, Inc. (“Gore”), a global materials science company, continues to build on its growing portfolio of protein capture devices with the introduction of its new 116mL and 232mL GORE® Protein Capture Devices with Protein A. The offerings follow commercial availability of its 58mL Protein Capture Device in Q4 of 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220405005200/en/

GORE Protein Capture Devices with Protein A (Photo: Business Wire)

GORE Protein Capture Devices with Protein A (Photo: Business Wire)

With these new, larger capacity 116mL and 232mL sizes, Gore continues to expand its GMP solutions, joining its current 9mL and 58mL devices. Additionally, Gore offers lab-scale sizes, 1.0mL and 3.5mL, for non-GMP applications. The 116mL and 232mL size high flow, high binding membrane chromatography columns are innovative tools in pre-clinical, and early clinical batch size applications. All of the devices use a unique expanded polytetrafluoroethylene (ePTFE) membrane that provides high dynamic binding capacity and short residence time, resulting in increased throughput and productivity. The consistent scaling of DBC and elution widths across sizes, and ability of the 58mL, 116mL and 232mL devices to operate at low pressure drop, makes them compatible with existing liquid chromatography (LC) systems.

“Gore continues to reinforce its leading membrane expertise with the creation of these 116mL and 232mL devices and is creating scalable solutions that don’t compromise performance for antibody-based therapies,” said William Barrett, Ph.D., Product Specialist for Gore PharmBIO Products.

He added, “We are proactively addressing process development needs and the larger GORE® Protein Capture Devices with Protein A provide another innovative solution for rapid purification of antibodies that alleviates bottlenecks and significantly boosts productivity with high binding capacity and fast flow rates.”

Key features of the 116mL and 232mL GORE® Protein Capture Devices with Protein A include:

  • High dynamic binding capacity (≥ 40 mg/mL) at short residence time (30 seconds)
  • Demonstrated ability to cycle 100 times with CIP
  • Low delta column pressure over cycling
  • GMP ready
  • Ready to use

Learn more about GORE® Protein Capture Devices with Protein A and get the latest information on upcoming events at www.gore.com/capturemoremAbs.

About Gore

W. L. Gore & Associates is a global materials science company dedicated to transforming industries and improving lives. Since 1958, Gore has solved complex technical challenges in demanding environments — from outer space to the world’s highest peaks to the inner workings of the human body. With more than 11,000 Associates and a strong, team-oriented culture, Gore generates annual revenues of $3.8 billion. For more information, visit gore.com.

Copyright: 
Copyright Business Wire 2022